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Tablets containing theophylline (66.67%) based on a Eudragit®
RS 30D and NE 30D matrices containing 10% to 30% of either
of the polymer were produced by compression method. The
influence of the different proportions of methacrylic esters, the
use of lactose and tribasic calcium phosphate as diluents and
also the effects of the addition of magnesium stearate as a
hydrophobic agent lubricant on the theophylline release, were
studied. Physicochemical analyses and drug content was
evaluated. In vitro drug release studies were carried out in
simulated gastric fluid without pepsin (pH1.2) and simulated
intestinal fluid without pancreatin (pH7.5). A relatively prolonged
release of theophylline from the polymer matrices for a 7 hr-
release period was detected. Magnesium stearate at 0.5% and
Eudragit® NE 30D at 10% was considered a better sustained-
release matrix compressed theophylline tablets comparing with
Eudragit® RS 30D in the same conditions (USP). Results from
physicochemical analyses were in accordance with specifications.
The release patterns were analyzed from the viewpoint of square-
root of time and as a first-order, zero-order kinetics, and Higuchi.
Additionally, half-life of release (Td
50%
) and dissolution rates (kd)
were calculated. Higuchi was the model that better fitted
theophylline kinetic, and diffusion controlled was involved.
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INTRODUCTION
In the last few years controlled release dosage forms
have made significant progress in terms of clinical
efficacy and patient compliance. The objective of
designing a controlled release system is to deliver drug at
a rate necessary to achieve and maintain a constant drug
blood level. Moreover these dosage forms have been
specially designed to release the drug slowly over several
hours, to protect the drug from the low pH of the stomach,
and/or to protect the stomach from the irritating effects of
the drug. Key advantages to the use of this technology are
prolonged activity, fewer doses, fewer side effects and
reduced toxicity. Too much of a medicinal ingested or
injected all at once in order to have a maintenance
concentration can mean wasted material or toxic side
E. Ojoe, E. M. Miyauchi, T. C. Viviani, V. O. Consiglieri378
effects. Decreasing the dose rate it is possible to avoid
these problems and to find a better efficacy results. A
major objective of the controlled release scientist is to de-
termine the best speed of release to obtain optimal
performance. The success of theophylline controlled
release as a bronchodilator to treat bronchitis is due to its
prolonged release rate (Acevez, Cruz, Hernandes, 2000;
Chambin et al., 2004; Myiagawa et al., 1996).
Theophylline, a bronchodilator, relaxes and opens the
air passages to the lungs, making it easier to breathe. This
drug is used mainly in solid oral dosage forms, particularly
slow release forms, and has a narrow therapeutic index,
requiring regular monitoring of serum theophylline
concentrations to avoid adverse effects (Turner-Warwick
1988; Montplaisir, Walsh, Malo, 1982)
It is possible to design systems with continuous and
uniform delivery of the drug, and the way to produce
controlled release include micro-encapsulation, film
coating, solid dispersions, and polymeric matrices.
Usually specially designed polymers are used to make this
control. Water insoluble materials like ethylcellulose have
been used in matrices to achieve controlled release of
drugs. Eudragit® RS 30D and Eudragit® NE 30D are able
to slow down drug diffusion very noticeably since they are
slightly swellable and slightly permeable. Their
permeability is comparable, but Eudragit® NE 30D
presents the advantage of being without any plasticizer
addition, different from RS 30D that requires 20% in
weight of triethylcitrate (Eudragit®, 2003) (Acevez, Cruz,
Hernandez, 2000; Pather et al., 1998, Salomon, Doelker,
1980).
The purpose of this work was to produce theophylline
release matrix tablets using Eudragit® RS 30D and NE 30D
and to evaluate the effect of these methacrylic acid esters
polymers with respect to polymer type and concentration,
diluent, magnesium stearate type intending to prevent the
mixture to adhere to the punches formers as lubricant to
control theophylline tablets release.
Theophylline was chosen as a model drug due to its
efficiency to treat chronic obstructive pulmonary disease,
and a narrow therapeutic index wich requires regular
monitoring of serum theophylline concentrations. In this
way slow release forms of theophylline can be used to
avoid adverse effects and promote its more efficient use
(Robinson, Eriksen, 1966; Hendeles, Weinberger,
Johnson, 1978).
MATERIAL AND METHODS
Reagents and Materials
The material used, in accordance with pharma-
ceutical grade of purity, were: anhydrous theophylline
(Ariston),  Eudragit® RS 30D (Rhöm Pharma),
Eudragit® NE 30D (Rhöm Pharma), triethylcitrate
(Rhöm Pharma), lactose M200 (Henrifarma), tribasic
calcium phosphate (Merck) and magnesium stearate
(Quimibrás Brasil). The reagents of analytical grade
were: potassium phosphate monobasic (Merck), sodium
hydroxide (Merck), sodium chloride (Merck), and
hydrochloric acid 37% (Merck). Anhydrous theophylline
99.80%, donated by Ariston, was used as reference
standard in quantitative determinations.
Tablet Preparation
Formulations of controlled release tablets were
prepared with different proportions of Eudragit® NE 30D
or RS 30D as polymers, using soluble and insoluble
diluents, and varying magnesium stearate percentages.
Tables I and II show matrices compositions, with Eudragit®
NE 30D and Eudragit® RS 30D, respectively.
Theophylline and diluents, either lactose or
tribasic calcium phosphate, were passed through a 60-
mesh sieve and thoroughly mixed in a conical blender
Multipex (Apex CO) for 15 minutes. Next, the mixture
was transferred to a Mullinex processor and either the
polymer (RS 30D) or the aqueous-based polymeric
suspension (NE 30D) was added. For formulations with
Eudragit® RS 30D, 20% in weight of triethylcitrate,
used as plasticizer, was added. The mixtures were
ground and simultaneously dried by hot air. The granu-
TABLE I - Composition of theophylline tablets formulated with Eudragit® NE 30D
Components (%) EUD NE 1 EUD NE 2 EUD NE 3 EUD NE 4 EUD NE 5 EUD NE 6 EUD NE 7
Anhydrous theophylline 66.67 66.67 66.67 66.67 66.67 66.67 66.67
Eudragit® NE 30D 10.00 20.00 30.00 10.00 20.00 30.00 10.00
Magnesium stearate 3.00 3.00 3.00 3.00 3.00 3.00 0.50
Lactose 20.33 10.33 0.33 - - - 22.83
Tribasic calcium phosphate - - - 20.33 10.33 0.33 -
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les formed were sieved using a sieve of 35 mesh and
dried at 50 ºC for 24 h. Magnesium stearate was added
and mixed for 10 minutes. The granules were com-
pressed in a single punch tablet machine (Fabbe), with
10 mm diameter (Ojoe et al, 2003).
Granulometric distribution
Granules produced before formulation compression
were submitted to granulometric analyses. The material was
sieved through several sieves progressively more fine-
meshed, aperture of 115-mesh sieve and shaken in a
mechanical shaker for 30 minutes followed by the calculation
in percentage of the amount of mass retained on each sieve.
Dissolution Studies
In vitro studies of theophylline release from the
prepared matrix tablets were conducted according to USP 25
, II apparatus at 37 ± 0.5 °C and padle speed of 50 rpm. The
dissolution studies were carried out for 7 hours; initial 1 hour
with 900 mL of simulated gastric fluid without pepsin (pH
1.2) and rest 6 hours in 900 mL of simulated intestinal fluid
without pancreatin (pH 7.5) under sink condition, performed
in a Hansson Research SRII 6-flask tester. At predetermined
intervals samples of 10 mL were withdrawn from the
dissolution medium and replaced with fresh medium to
maintain a constant volume. After centrifugation and
appropriate dilution, the sample solution was analyzed at 270
nm (pH 1.2) and 277 nm (pH 7.5) by a UV spectro-
photometer (Shimadzu, UV-1601). The amounts of drug
present in the samples were calculated with the help of
appropriate calibration curves constructed from reference
standards. Drug dissolved at specified time periods was
plotted as percent release versus time (hours) curve.
Different kinetic equations (zero-order, first-order
and Higuchi’s equation) were applied to interpret the
release rate from matrix system using linear regression. The
dissolution rate (kd), correlation coefficients (r), and half-
life of release (Td
50%
) were also determined.
Additional Tests
Tablet hardness was measured with a Pharma Test
PTB 311 tester. The hardness (kgf) of 10 tablets was
measured, and the mean hardness was calculated and
reported.
The tablet friability was determined on a Coel HX-4
friabilator. The weight of 20 tablets was measured on an
analytical balance (Mettler H15) and then loaded into the
friabilator. After 100 revolutions, the tablets were removed,
dedusted, and reweighed. The difference of the weight was
calculated as a percent loss.
Diameter and thickness were measured using
Paquimetre Mitutoyo for 10 tablets.
To study weight variation, 20 tablets were weighed
individually using an electronic balance (Mettler H15), and
the test was performed according to the official method.
The drug content was determined as described
above; five tablets were weighed and crushed. The
amount of powder equivalent to the mean of these five
tablets was weighed in 100 mL of water and the volume
adjusted to 200 mL. After 20 minutes of centrifugation,
aliquots of 1 mL were taken from this solution and
diluted to 100 mL with simulated gastric fluid without
pepsin (pH 1.2) and simulated intestinal fluid without
pancreatin (pH 7.5). Absorbancies of resulting solutions
were measured in a spectrophotometer at 270 nm for pH
1.2 and 271 nm for pH 7.5. Simultaneously, a 10 µg/mL
theophylline standard solution prepared in the same
medium (pH 1.2 and 7.5) was recorded. Content of
theophylline was calculated. The drug content test was
carried in duplicate.
RESULTS AND DISCUSSION
The granulation process to obtain matrices showed
difficulties with the increasing percentages of Eudragit®.
The hard homogeneous mass formed during this process
in some lots of tablets seemed to pass through the mesh
35 sieve with difficulty. Consequently, resulted in less
TABLE II - Composition of theophylline tablets formulated with Eudragit® RS 30 D
Components (%) EUD RS 1 EUD RS 2 EUD RS 3 EUD RS 4 EUD RS 5 EUD RS 6 EUD RS 7
Anhydrous theophylline 66.67 66.67 66.67 66.67 66.67 66.67 66.67
Eudragit® RS 30D 10.00 15.00 20.00 10.00 15.00 20.00 10.00
Trietylcitrate 2.00 3.00 4.00 2.00 3.00 4.00 2.00
Magnesium stearate 3.00 3.00 3.00 3.00 3.00 3.00 0.50
Lactose 18.33 12.33 6.33 - - - 20.83
Tribasic calcium phosphate - - - 18.33 12.33 6.33 -
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efficiency and low productivity. Considering the
polymer Eudragit® RS 30D, there was a limitation when
amounts of the polymer, higher than 20%, were applied.
Even when Eudragit® NE 30D was used, the amounts of
20% and 30% also showed difficult ies.  During
granulometric analyses, the granules obtained in lots
EUD NE 2, EUD NE 3, EUD NE 5, and EUD NE 6
presented less than 10% of fine powder, when passed
through sieve aperture of 115 mesh. According to
Salomon and Doelker (1980), these quantity of fine
powder is considered ideal, once large quantities can
lead to an elastic characteristic in pharmaceutical
dosage forms, increasing the volume of tablet during the
compression process. This volumetric increase makes
hydration and diffusion easy, thus resulting in high
amount of drug released. This phenomenon probably
contributed to increase the amount of drug released from
lots EUD NE 1, EUD NE 4, and EUD NE 7 (Figure 1
and 2), which granules presented high percentages of
fine powder (Table III). The granules produced with
Eudragit® RS 30 D polymer, with high percentage of fine
powder were in lots EUD RS 4, EUD RS 5, EUD RS 6
and EUD RS 7 (Table IV).
In accordance with pharmacopoeia specifications
(United States Pharmacopoeia, 2002; Farmacopéia Bra-
sileira, 1988), tablets between 200 and 300 mg, may have
a variation around 7.5% of the labeled weight. The
weights of the formulations EUD NE 6, EUD RS 1, and
EUD RS 2 (Table V) were in accordance with the
pharmacopoeia limits but the coefficients of variation
showed that they could be out of the tolerance limits.
Friability is an important parameter related to mechanical
resistance of tablets.
All formulations were compliant with official
friability specifications (Table V), which allow not more
than 1% of mass lost on 20 tablets weight. Hardness can
affect the disintegration rate of tablets and consequently,
drug dissolution. Hardness of the tablets were in
conformity with pharmacopeial tolerance limits except
formulations EUD NE 6 and EUD RS 2, in which
hardness for values were lower than the limit of 4.6 kgf.
However, this fact did not affect theophylline release in
tablets, but can facilitate drug release by encreasing
permeability of the drug in solution. The content of the
drug in the tablets were determined following USP 25
specifications which stated that the quantity of drug in
TABLE III - Granulometric analyses of formulations prepared with Eudragit® NE 30D
Mass retained on the sieve (%)
Tyler (Mesh) EUD NE 1 EUD NE 2 EUD NE 3 EUD NE 4 EUD NE 5 EUD NE 6 EUD NE 7
35 0,15 0,07 59,37 51,32 64,02 55,43 13,83
48 10,22 33,25 39,22 9,28 17,27 13,68 6,49
60 3,30 31,29 1,41 10,49 5,61 12,68 1,37
65 32,64 25,70 0,08 5,45 3,62 13,18 28,11
80 0,11 0,29 0,04 5,98 2,97 0,41 15,73
100 0,04 0,07 0,04 0,98 1,83 0,16 0,00
115 0,07 0,25 0,03 0,64 0,12 0,04 4,15
>115 53,48 8,96 0,67 15,26 0,08 1,33 28,49
TABLE IV - Granulometric analyses of formulations prepared with Eudragit® RS 30D
Mass retained on the sieve (%)
Tyler (Mesh) EUD RS 1 EUD RS 2 EUD RS 3 EUD RS 4 EUD RS 5 EUD RS 6 EUD RS 7
35 7,16 25,68 47,91 1,42 4,69 18,94 3,33
48 37,05 25,30 10,01 8,53 9,67 12,09 4,17
60 4,77 1,79 2,05 8,79 8,05 4,84 11,87
65 17,11 18,66 8,11 26,14 19,94 8,43 8,46
80 35,48 22,89 0,29 42,01 18,25 8,00 4,33
100 0,27 0,79 0,14 0,54 1,31 6,17 10,07
115 0,07 0,16 0,07 0,15 5,51 5,34 1,76
>115 0,00 0,05 0,00 12,45 32,58 32,03 56,43
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tablets should not be less than 90.0% or more than
110.0%. All drug contents in formulations were between
these limits.
Dissolution Studies
In vitro dissolution studies are valuable tools to judge
quality and stability of sustained release dosage forms and
are often used to predict in vivo performance.
As can be observed in Figures 1 and 2, both
polymeric materials (Eudragit® RS 30D and NE 30D) were
able, in first instance to produce true matrices, influencing
the release profile of theophylline. Therefore in polymer NE
30D, an increase in its content, more than 10% of the
polymer and tribasic calcium phosphate used as diluent, did
not result in a different profile of theophylline release in
formulations (Figure 1).
Some of the reasons that led to the stabilization of
theophylline profile when different amounts of Eudragit®
NE 30D were used, could be related to the large quantity
of polymer applied, theophylline solubility or the
utilization of 3% of magnesium stearate, an hydrophobic
lubricant that decreases theophylline release in
formulations. Moreover, the use of an insoluble
excipient like tribasic calcium phosphate could also
decrease drug release, diminishing the matrix hydration.
TABLE V - Results of weight, friability, diameter, thickness, hardness, and drug content of theophylline
Formulations Weight Friability Diameter Thickness Hardness Drug content
(mg) (%) (mm) (mm) (kgf) (%)
EUD NE 1 303.19 (4.56) 0.28 10.01 (0.02) 4.00 (0.38) 6.73 (0.22) 98.14
EUD NE 2 301.49 (3.38) 0.22 10.00 (0.01) 4.37 (0.08) 5.56 (0.15) 99.38
EUD NE 3 302.33 (5.50) 0.12 10.00 (0.01) 4.31 (0.02) 5.31 (0.10) 92.74
EUD NE 4 298.85 (3.19) 0.37 10.03 (0.02) 4.14 (0.08) 5.05 (0.09) 99.18
EUD NE 5 301.90 (2.21) 0.11 10.02 (0.02) 4.11 (0.06) 7.10 (0.11) 95.20
EUD NE 6 289.47 (7.54) 0.15 10.01 (0.01) 4.21 (0.17) 4.39 (0.08) 97.97
EUD NE 7 320.64 (6.84) 0.42 10.01 (0.04) 3.98 (0.35) 9.59 (0.46) 93.70
EUD RS 1 305.15 (10.13) 0.55 10.04 (0.03) 4.00 (0.07) 5.46 (35.4) 95.44
EUD RS 2 291.35 (7.92) 0.36 10.04 (0.02) 3.77 (0.03) 3.47 (7.5) 99.33
EUD RS 3 303.15 (4.36) 0.23 10.02 (0.02) 3.89 (0.07) 5.56 (11.5) 96.67
EUD RS 4 300.99 (5.17) 0.51 10.04 (0.03) 4.02 (0.12) 9.39 (3.10) 99.48
EUD RS 5 306.96 (4.79) 0.63 10.05 (0.03) 3.86 (0.11) 6.84 (16.1) 91.36
EUD RS 6 305.26 (6.53) 0.40 10.02 (0.02) 5.10 (0.05) 5.20 (4.50) 96.02
EUD RS 7 301.40 (1.45) 0.09 10.06 (0.03) 3.81 (0.31) 10.97 (4.20) 96.28
Coefficients of variation (%) in parenthesis.
FIGURE 1 - Release profiles of theophylline tablets with Eudragit® NE 30D with lactose and tribasic calcium phosphate
respectively, applying USP 25 ed. dissolution test (Test 10).
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In formulations such as EUD RS 1, EUD RS 2, and
EUD RS 3, where the diluent content was lactose,
different release of the drug was evident when the
medium was changed from pH 1.2 to pH 7.5 (Figure 2)
probably related with the characteristics of polymer
solubility. In formulations with 10% of polymer, the
decrease in lubricant content from 3% in EUD RS 1, to
0.5% in EUD RS 7, had no influence on theophylline
release in tablets.
An ideal matrix system is that in which the drug
released constantly, from the beginning to the end, in a zero
order kinetic model (Pather et al., 1998; Ishikawa et al.,
2000; Robinson, Eriksen, 1966). Drug release from matrix
tablets, in general, becomes progressively slower with time,
like Higuchi’s model, in which the amount of drug released
is proportional to the square root of time (Higuchi, 1963).
Kinetic models which fit zero order and Higuchi are
more suitable for controlled release formulations, while
first order model is more appropriate for conventional
tablets (Higuchi, 1963). The best fit with higher correlation
(r2 > 0.98) was found with the Higuchi’s equation for the
majority of formulations (Table VI). This fact was expected
considering that difusion is the preferential mechanism of
drug release from this kind of matrices. On the other hand,
FIGURE 2 - Release profiles of theophylline tablets with Eudragit® RS 30D with lactose and tribasic calcium phosphate
respectively applying USP 25 ed. dissolution test (Test 10).
TABLE VI - Kinetic assessment: correlation coefficient (r) of kinetic model, dissolution rate (k) and half-life of release (t
50%
)
Formulations Correlation coefficients (r) k (min-1) t
50% 
(min)
Zero Order First Order Higuchi
EUD NE 1 0.8465 0.9188 0.9652 0.0287 294.47
EUD NE 2 0.9485 0.9655 0.9666 0.0194 675.19
EUD NE 3 0.9522 0.9747 0.9901 0.0192 711.39
EUD NE 4 0.9068 0.9361 0.9755 0.0226 555.37
EUD NE 5 0.9475 0.9693 0.9788 0.0197 662.60
EUD NE 6 0.9526 0.9699 0.9720 0.0230 542.08
EUD NE 7 0.9398 0.9812 0.9977 0.0438 141.81
EUD RS 1 0.9275 0.9743 0.9915 0.0321 271.38
EUD RS 2 0.8355 0.8909 0.9635 0.0249 375.95
EUD RS 3 0.9216 0.9641 0.9979 0.0224 478.91
EUD RS 4 0.8496 0.9274 0.9743 0.0312 222.03
EUD RS 5 0.9046 0.9481 0.9866 0.0278 340.79
EUD RS 6 0.9387 0.9661 0.9924 0.0198 691.85
EUD RS 7 0.9405 0.9875 0.9985 0.0326 252.77
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theophylline although being a slight soluble drug, released
from Eudragit® matrices by diffusion and not by erosion,
considering that the matrices maintained their original
shape from the start to end of dissolution tests.
CONCLUSION
At present, the polymers studied in this work are
used extensively in pharmaceuticals to control the release
of drug. The approach of the present study was to make
a comparative evaluation among these methacrylic esters
polymers and to find out factors involved on drug release
profile. The type of polymers used imparts a conspicuous
effect on release mechanism. The lubricant, magnesium
stearate, at low concentration improved theophylline
release in tablets prepared with Eudragit® NE 30D. The
correlation values obtained when mathematical models
were applied to release data suggested that the releases of
drug from these tablets were preferentially a diffusion-
controlled process. According to USP 25, formulation
EUD NE 7 showed amount of dissolved theophylline close
to specifications in Test 10.
RESUMO
Desenvolvimento e avaliação in vitro de comprimidos
de liberação prolongada de teofilina preparados com
Eudragit®
Comprimidos contendo teofilina (66.67%) e polímeros
de Eudragit® NE 30D e RS 30D entre 10 e 30% foram
produzidos por compressão. A influência das diferen-
tes proporções de ésteres do ácido metacrílico, uso da
lactose e fosfato de cálcio tribásico como diluente, bem
como os efeitos da adição de estearato de magnésio
como agente lubrificante hidrofóbico na liberação da
teofilina foram estudados. Análises físico-químicas e
teor de fármaco foram avaliados. Estudos da liberação
do fármaco in vitro foram conduzidos em fluido gástri-
co simulado (pH 1,2) e fluido intestinal simulado sem
pancreatina (pH 7,5). Observou-se liberação prolonga-
da relat iva de teofi l ina part indo de polímeros
matriciais, em 7 horas de dissolução. Estearato de
magnésio a 0,5% e de Eudragit® NE 30D a 10% foi
considerado o sistema de liberação adequado para
comprimidos matriciais comparado com de Eudragit®
RS 30D nas mesmas condições (USP). Os resultados
das análises físico-químicas apresentaram-se dentro
das especificações. Modelos matemáticos de ordem
zero, primeira ordem e Higuchi foram aplicados para
estudar a liberação de teofilina nos comprimidos. Adi-
cionalmente, foram calculadas a meia-vida (Td
50%
) e a
velocidade de dissolução (kd). O modelo de liberação
de Higuchi foi o que melhor representou a liberação do
fármaco nos comprimidos, sendo demonstrado que o
principal mecanismo de liberação foi a difusão.
UNITERMOS: Teofilina. Matrizes. Liberação prolonga-
da. Ésteres do ácido metacrílico.
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